Quick Answer
CHINA PHARMA HOLDINGS, INC. reported Operating Income Loss of -$4.59 million for the year ending 2024.
- CHINA PHARMA HOLDINGS, INC. showed a decrease of -66.8% in Operating Income Loss from 2023 to 2024.
- This data is from CHINA PHARMA HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2010 to 2024 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2010: $6.20 million | Q1 2011: $5.34 million | Q2 2011: $5.76 million | Q3 2011: $5.96 million | Q1 2012: $3.41 million | Q2 2012: $2.21 million | Q3 2012: $1.62 million | Q1 2013: -$3.00 million | Q2 2013: -$4.76 million | Q3 2013: -$2.69 million | Q1 2014: -$2.34 million | Q2 2014: -$8.53 million | Q3 2014: -$5.99 million | Q1 2015: -$3.76 million | Q2 2015: $1.44 million | Q3 2015: $3.19 million | Q1 2016: -$1.32 million | Q2 2016: -$2.22 million | Q3 2016: -$1.55 million | Q1 2017: -$802.6 thousand | Q2 2017: -$2.13 million | Q3 2017: -$2.06 million | Q1 2018: -$140.7 thousand | Q2 2018: -$864.4 thousand | Q3 2018: -$1.93 million | Q1 2019: -$334.2 thousand | Q2 2019: -$753.0 thousand | Q3 2019: -$645.2 thousand | Q1 2020: -$599.3 thousand | Q2 2020: $75.0 thousand | Q3 2020: -$952.5 thousand | Q1 2021: -$696.5 thousand | Q2 2021: -$752.9 thousand | Q3 2021: -$762.4 thousand | Q1 2022: -$911.7 thousand | Q2 2022: -$779.6 thousand | Q3 2022: -$688.7 thousand | Q1 2023: -$397.5 thousand | Q2 2023: -$456.3 thousand | Q3 2023: -$713.5 thousand | Q1 2024: -$916.1 thousand | Q2 2024: -$1.39 million | Q3 2024: -$1.09 million | Q1 2025: -$758.6 thousand | Q2 2025: -$652.1 thousand | Q3 2025: -$628.1 thousand.
- Over the full 15 years of available data (2010 to 2024), CHINA PHARMA HOLDINGS, INC.'s Operating Income Loss has declined by 118.6%.
- Historical annual values: Fiscal year 2024: -$4.59 million | Fiscal year 2023: -$2.75 million | Fiscal year 2022: -$3.55 million | Fiscal year 2021: -$2.86 million | Fiscal year 2020: -$2.58 million | Fiscal year 2019: -$20.41 million | Fiscal year 2018: -$10.45 million | Fiscal year 2017: -$18.68 million | Fiscal year 2016: -$8.16 million | Fiscal year 2015: -$14.30 million | Fiscal year 2014: -$38.76 million | Fiscal year 2013: -$18.61 million | Fiscal year 2012: $5.91 million | Fiscal year 2011: $22.03 million | Fiscal year 2010: $24.66 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: